相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers
Yanli Wang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Axial spondyloarthritis: new advances in diagnosis and management
Christopher Ritchlin et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Cost to Medicare of Delayed Adalimumab Biosimilar Availability
ChangWon C. Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Jinmei Su et al.
BIODRUGS (2020)
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
Mark C. Genovese et al.
RMD OPEN (2020)
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial
Baili Chen et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
Xiaojian Ji et al.
BIOMED RESEARCH INTERNATIONAL (2019)
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2019)
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
Stanley Cohen et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists
Hiroki Mitoma et al.
CYTOKINE (2018)
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
L. Cai et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
Stanley Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register
Elisabeth Lie et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
A. S. Strik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects
Christopher Wynne et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Ankylosing Spondylitis and Axial Spondyloarthritis
Joel D. Taurog et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis
Judith A. Smith
CURRENT ALLERGY AND ASTHMA REPORTS (2015)
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab
Desiree van der Heijde et al.
RHEUMATOLOGY (2015)
Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial
Feng Huang et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents
Xin Gao et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis
Martin Rudwaleit et al.
JOURNAL OF RHEUMATOLOGY (2009)
Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice
Dirk Elewaut et al.
RHEUMATOLOGY (2009)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
分享论文
